top of page
1290.jpg
1291.jpg
1293.jpg

業種別ソリューション                                           STOP COVID-19　×　cutting-edge technologies Technology

HOCITGROUPでは、官公庁や自治体、金融機関、様々な業種の企業へ向けた、情報システムの構築を行っています。

Industry solutions

HOCITGROUP builds information systems for government agencies, local governments, financial institutions, and companies of various industries.

行业解决方案
HOCITGROUP为政府机构，地方政府，金融机构和各个行业的公司构建信息系统。

お問い合わせ联系我们Contact Us

mv_government.jpg

官公庁・自治体

Government/Local government

政府/地方政府

mv_education.jpg

教育

Education

https://www.nekkyo.org/

Recruit

https://www.oxhabridge.com/

mv_healthcare.jpg

医療・ヘルスケア

医疗/保健

Medical/Healthcare

mv_finance.jpg

金融

Finance

1294.jpg
mv_manufacturing.jpg

製造

Manufacturing

mv_telecommedia.jpg

通信・放送

​Communication/broadcast

mv_utility.jpg

電力・ガス・水道

Electricity, gas, water

电，气，水

hero_individual_pc (1).jpg

個人のお客様向け

For individual customers

对于个人客户

mv_distribution.jpg

流通

distribution

mv_construction.jpg

建設・不動産

Construction/Real Estate

mv_agriculture.jpg

食農・農業

粮食和农业

Food and agriculture

01.-AIチャットボットのすべて！導入前に知るべき6つのポイント.jpg

AI×design＆AI×Animation Technology

​https://www.cjdla.com/

1292.jpg
1286.jpg

AI×design＆AI×Animation Technology   

「創造性を科学し、世界中の誰もが社会価値創造に貢献できるエコシステムを構築する」をミッションとし、人の価値を資本により良い世の中が実現されるよう、様々なプロダクトの企画・開発・運営を行なっています。そのうちの一つ、特許技術であるCI技術（コンセンサスインテリジェンス技術）とは、独自の合意形成アルゴリズムにより、AIでは解決不可能な「教師データのない『定性的な価値』を定量化できる技術です。これにより、これまで定量化できなかった人の創造性やセンスといった「感覚的資産」を全て客観的に定量化し、ブロックチェーン技術と組み合わせて流通させることで、新たな「価値経済」を創造することが可能になります。アイデア測定＆創出ツールai design独自の特許技術を駆使し、感覚的なクリエイティブ能力を数値化することができる、人のアイデアを科学するプロダクトです。
これまで行われきた適性検査などとは一線を画す、人々が正確に評価をすることが難しいと考えられていたアイデアを相対的に数値化し評価することができるサービスです。
ai designを科学し、数値化することで、多くの人が潜在的に隠し持っているクリエイティブ能力の価値を発見することができるようになります。
そこで見い出された評価結果を元に、例えば社内の新規事業企画、最適な人事配置、採用・研修など目的に応じ活用することが可能となりますの研究、普及、そしてこの技術を活用したイノベーションの創出を目指すため、日本を代表する企業が集まる「HOCITGROUP」を設立しました。AI促進を目指す先駆的企業が、HOCITGROUP」に関する共同研究を行うことにより、コミュニティ形成やオープンイノベーションが可能な基盤を強化します。CI技術（コンセンサスインテリジェンス技術）を用いたアイデア創造の場の提供等を定期的に行い、各企業の「HOCITGROUP」力」の強化や新規事業創出の加速化と共に、HOCITGROUP」という新たな文化を醸成していきます。。

02.-チャットボットとは？今更聞けない人のために超解説！.jpg

Album-RPA特許-YEARBOOK 

dddgggg.jpg
gggggdddd.png
hgfff99.jpg
ggddddt.png
zzzzzzzzzz.jpg
cccgf.jpg
hhhh88767.jpg
jjjj7777.png
fdd4.png
ccc.jpg
ccxxx.jpg
ggg55.png

Company information
•    Office
• Leather
•    access

Company name
HOC Intelligent Technology Co., Ltd.
Established
September 2nd year of Reiwa
Representative
Representative Director and President Tahara
Capital
6 million yen
number of employees
50 people (including contract employees)
Corporate philosophy
Mutual music, co-cultivation, co-op
Creating value and connecting to the future
• Trust
• Worth
• Intelligence
• Communication
• Economy
Business content
System design/development
• Planning/analysis/construction/design/development/support
• ・Comprehensive consulting for new installation/rebuilding
Planning design/production
• Website, printed matter, CI, etc.
Bank
Sumitomo Mitsui Mitsubishi
Customer
Lawyer, tax accountant, company employee
Member
Osaka Chamber of Commerce and Tokyo Chamber of Commerce
Affiliate
China, China Harbour Bridge, Intelligence Technology Nanjing, Shanghai, Hangzhou, etc.
              
Osaka Head Office
577-0831
4-9-35, Shundecho, Higashiosaka, Osaka Prefecture
TEL 090-8747-9395
Tokyo branch
〒108-0073
Minato-ku, Tokyo
Osaka Head Office
5 minute walk from Kintetsu Fuse Station, Osaka City
Tokyo branch
5 minutes walk from Akabashi Station on the Toei Oedo Line

History
• July 1st year of Reiwa Established HOCIT GROUP
• September 1st year of Reiwa   Acceptance of specified worker dispatch business (Special 27-305254)
• September 1st Reiwa   Joined the Osaka Chamber of Commerce
• September 1st Reiwa   Employee training
• October 1st Reiwa  Opened office in Tokyo
• July 2nd year of Reiwa   First anniversary of HOCIT GROUP
• August 1st year of Reiwa   Acquired privacy mark
• 2 years in Reiwa   Increased capital to 6 million yen
Business content

System design/development
• Planning/analysis/construction/design/development/support
• ・Comprehensive consulting for new installation/rebuilding
Planning design/production
• Website, printed matter, CI, etc.
System planning/design/development/construction
We provide resident development support for business users, SIers, and manufacturers.
• Proposal and development of business applications
• Construction and development of software using multimedia software and general-purpose machines
• Network construction/server setting, operation management
• System engineering sales support
Matter
C/S system development
• Language: VB, VB.NET, Delphi, PowerBuilder, C, C++, VC++, PL/SQL, etc.
• DB: SQLserver, Oracle, DB2, PostgreSQL, MySQL, etc.
WEB system development
• Language: Java, VB.Net, JSP, C#, PHP, Perl, CGI, etc.
• DB: SQLserver, Oracle, DB2, PostgreSQL, MySQL, manufacturer RDB, etc.
• FW: WAS, Struts, WebSphere, Nexaweb, VisualStudio etc.
General-purpose machine system development
• Language: Cobol, ProCobol, PL/1 etc.
• DB: ADABAS, AIM, DB2, VIS, etc.

Website planning, design, production and management
We support various design projects from websites to paper media.
• Homepage creation/WEB content construction
• Graphic design such as CI and logo mark
• Handling of public relations, advertisements, newspapers and displays
• Production of printed materials (business cards, brochures, etc.)
• Product development, package design, etc.
Contact us by email, phone or fax,
We accept various quotes and consultations
Please tell our staff about your budget, delivery date and what you want to make.
In cases such as "I do not understand the system well" "It is difficult to explain well",
If you give us a rough image, we will propose an appropriate system.
We also accept face-to-face consultation, so please contact us if you wish.

Employment information
Sales
Being grateful is the driving force! Recruiting sales jobs that connect people to companies!
We will face the challenges from the same perspective as our customers,
After closely examining and organizing the customer's requests and thoughts,
Plan and create creatives.
We deliver proposals for solving customers' problems, not "making and ending".
"Collaboration to Goal-Achieving in Cooperation"
With this philosophy in mind, we are delighted to work together with our internal members as well as our customers.
Why do
Are working on]
We are a creative group that provides "optimum" and "creation" to our customers.
Our goal is to improve our expertise in various fields such as planning/suggestion, direction, production, system development, marketing, and human resource services, and to solve by various means. In addition, we think that we can truly solve the client's problems and expand the business by operating the PDCA instead of making it and making it.
Find what you want to achieve and find what you want.
Face your challenges as a matter of your own.
If we think from the customer's perspective with a sense of ownership, we will be able to highlight customer issues that were previously invisible.
Working closely with our customers makes it fun to work with.
How are you doing
•
It is a flat relationship with the management and an environment where they can accept their opinions.
•
We keep close contact with customers
[Respect individuality and accept diversity]
Even if I didn't get good results yesterday, today I will change my mind and start from scratch.
We do our best to clarify the issues, set goals, and achieve results while performing self-management and schedule management.
Such positive feeling and stoicness are one of the factors that can be utilized in sales.
And it's not just those who are good candidates for sales.
You can call the person who dropped the handkerchief without hesitation.
You can speak to yourself if you are not in the conversation.
When you are walking in a narrow alley, naturally you will pass the opponent first,
As I pass in front of the TV in the waiting room of the hospital, I bend over and become fast.
It is an essential element for sales to be able to naturally pay attention to such things.
If you've been told that emails are always answered quickly, that's another factor you can use in sales.
Everything is your "individuality" that leads to sales.
We will work together to achieve our goals and grow with the company, while respecting the individuality of each individual.
We are looking for members who can work together in such an environment.
I will do this
[What is Novita's sales job? ]
"Thank you." "Thanks to you."
The department that can hear these words the most is our sales department.
And this is the driving force of our work.
The strength of our sales department at Novita is "continuous relationships".
It's not "finishing and ending", but "starting after closing".
We believe that communication after signing a contract is an important part of sales, not to mention the role of connecting companies and people looking for work.
We carry out regular follow-ups, and we thank both the company and those who are employed.
The department manager usually puts antennas in various places and gathers information and prepares in advance.
That's all because we want to accurately capture the needs of our customers and solve their problems.
Under the head of such a department, the members of the sales department value the achievement of the team rather than achieving it alone.
[Believe in all possibilities and continue to challenge them]
In addition to web production, Novita is actively engaged in new initiatives such as new businesses.
That is why we can offer various suggestions and experience in sales of Novita.
A series of new discoveries because there is an opportunity to propose multiple products rather than handling one “thing”.
It is the perfect workplace for you who want to continue to take on challenges.
"Job Description"
Mainly, you will be the bridge between those who are looking for a job and the companies who are looking for people.
Whether you are looking for a company or a job, we continue to follow the concept of "starting after making a contract" rather than "ending after introducing".
I often go outside the company for meetings and interviews, and often interact with people.
Our senior employees will support you, so you can immediately discuss your concerns and anxieties!
《Indispensable experience/skills》
・General Microsoft Office (especially Excel, Word, PowerPoint)
・Those who are aware of sales plans and sales
《Welcome skill》
・Experience in human resources service
・Those who are interested in various things and want to work on it
・Those who like talking to people
・People who like to think close to their customers
If you have any interest, please do not hesitate to apply! We'll be expecting you!

 


programmer
Recruitment
Web programmer
Those who have experience of development with Android or virtualization preferential treatment
Qualification requirements
Work experience 1 year or more
Employment status
Full-time employee (trial period 6 months)
Application details
• ・Programming of core system development (Web system, open system, control system, etc.)
• Core system design/development support work (resident dispatch to major vendors)
• Experienced in web system development using JAVA, PHP, C#, .NET
• Anyone who has experience since detailed design
• Those who can handle office software without difficulty
• Those who can communicate with others and work
bonus
Twice a year (summer and winter)
Work location
Our company or Kinki area/Metropolitan area (client)
Working hours
9:00 to 18:00 (break 60 minutes) *Overtime/holiday work available
Holiday vacation
• Saturday, Sunday and public holidays
• Summer vacation, New Year holidays
• · Holiday
Benefits and benefits
• Retirement allowance system
•    ·Employment insurance
• Labor accident
• Social insurance (health insurance, welfare pension)
•    ·paid holidays
• · Allowance
 

Welcome to the entrance to the world of acupuncture
Acupuncturist: a profession that will not disappear in the AI ​​era
With the development of AI (artificial intelligence), many existing occupations are expected to disappear. It is said that artificial intelligence has gradually entered the high-level intellectual professional fields such as finance and legal affairs, and has begun to serve people.

But what about acupuncture?

Acupuncture is a delicate and special technique that cannot be easily replaced by computers or machines. It can only be done manually. We often hear about their physical conditions from patients, consider the cause of the current symptoms, and select appropriate treatment points from 361 acupoints (acupoints) for acupuncture. This is a complex and delicate technique. It is impossible for robots. Even if it is possible, it will not be controlled by practitioners.

On the contrary, since it is surrounded by digital devices every day, do you think it needs the warmth, softness and safety of human hands? Acupuncture is a technology that is expected to become more valuable in the future AI era.

The WHO (World Health Organization) has also certified the therapeutic effects of acupuncture. Acupuncture therapy is good at treating symptoms that are difficult to improve by Western medicine, pain that has not been diagnosed as "discomfort" (discomfort) according to the examination results, and pain that cannot be completely cured. It is understandable that in recent years, the upsurge of Oriental medicine is coming, and it is said that this is a very stressful society. There is a growing demand for acupuncturists who can understand and treat patients' pain.

In addition, acupuncturists are long-term participants of men and women. This is not hard work, so even after aging, you can use the skills and intuition accumulated according to your physical strength to stand in the field of treatment. This is a lifelong job, you can improve your skills while you work, and cultivate opportunities for success while reaping rewards.
 

ACCELERATE OUTCOMES WITH A BACKBONE FOR ARTIFICIAL INTELLIGENCE.

makes machine learning operational by connecting models to the real-world decisions they inform. Often, AI/ML algorithms live in experimental vacuums. Foundry provides the end-to-end infrastructure an organization needs to apply AI/ML to real problems and real data:

  • A data foundation.  provides the data engineering capabilities an organization needs to deploy AI/ML models it can trust. Organizations use  to build a solid foundation of sufficient, quality data, then bring that data into daily operations.

  • Production deployment infrastructure. revolutionizes the way organizations build and deploy AI/ML by combining a data foundation with end-to-end algorithm deployment infrastructure. Data scientists and engineers can customize, deploy, assess, and compare across homegrown, open-source, and third-party algorithms. All models are tightly integrated with end-to-end platform capabilities, ranging from feature curation and health checks to model management to inference/serving to outcome monitoring.

  • Faster feedback loops. AI/ML models rarely work on a "set it and forget it" basis.  integrates the full model lifecycle with end user actions and feedback, and with operational decisions and outcomes. This enables operationally oriented model monitoring, management, understanding, selection, and adjustment. The result is more adaptable and ambitious AI/ML, faster.

UNITE THE ORGANIZATION AROUND A SHARED ENVIRONMENT FOR MACHINE LEARNING.

The most effective AI/ML encodes and supercharges an organization's unique expertise. That requires uniting an organization's data scientists, decision-makers, and everyday employees in an environment for collaborating on AI/ML-powered operations.  collaboration infrastructure drives AI/ML that brings the organization together:

  • A unifying ontology. ontology translates an organization's complex data landscape into human-readable concepts. built models reflect how an organization views the world and unite data scientists, engineers, analysts, executives, and operational end users around a common semantic layer.

  • Granular security controls. lets organizations define granular access control policies at the integration stage, then propagates those policies intelligently across the system. Organizations can promote collaboration confidently with granular data security and transparent data governance.

  • Model templates.model templates empower low-code and no-code AI/ML so even non-technical users can use AI to accelerate and enrich their workflows.

MAXIMIZE IMPACT AND MINIMIZE RISK WITH A PLATFORM DESIGNED FOR RESPONSIBLE ENGINEERING.

Our approach to AI/ML in  reflects our foundational belief in augmenting human intelligence, not replacing it. We believe AI/ML algorithms are most effective when they empower humans to ask complex questions, interpret answers, and act on results. At public and private sector organizations around the world, driven AI/ML is accelerating human decision-making by:

  • Surfacing new leads in dark web, weapons trafficking, financial fraud, and drug trafficking investigations so investigators can identify persons of interest more quickly

  • Aggregating and correlating biomedical research data to streamline drug discovery

  • Processing entity resolution suggestions so analysts can focus on making assessments rather than manually sorting and tagging data

  • Analyzing massive-scale sensor data so that engineers can make better aircraft maintenance decisions

  • Rapidly generating simulations while allowing operators to tweak scenario variables, leading to better-informed decisions optimized for different variables (e.g., safety rating and production quantity)

I see our approach to ethical machine learning as being grounded in an appreciation for both the promise and limitations of human-computer collaboration. The promise of AI is in augmenting and enhancing human intelligence, expertise and experience. Think helping a aircraft mechanic make better, more accurate and more timely repairs – not automating the mechanic out of the picture.

— Anthony Bak, Co-Lead of Palantir's Machine Learning team, in an interview with CTOVision

Protecting privacy and preserving civil liberties is fundamental to our mission.ships with technical capabilities that enable ethical engineering and ethical machine learning, including data protection features such as granular access controls, data provenance and lineage tracking, data retention and deletion management, and audit logging.  also enables industry-leading monitoring and validation for AI models. Its flexible, configurable tools let organizations evaluate model bias, in terms of both the data used to train the model and model outcomes.

We recognize that technology alone can't fully mitigate the risks of machine bias. Our dedicated Privacy and Civil Liberties team works with our engineers and our customers to approach building and deploying AI/ML thoughtfully.

Acupuncture significantly reduces AI-associated arthralgias

Publish date: December 8, 2017

By 

Roxanne Nelson

 

 

 

REPORTING FROM SABCS 2017

SAN ANTONIO – Acupuncture significantly reduced joint pain that was associated with the use of aromatase inhibitors (AIs) in women with early breast cancer, according to new findings reported at the San Antonio Breast Cancer Symposium.

The randomized, phase 3 SWOG S1200 clinical trial found that, compared with sham acupuncture and a control group receiving no therapy, women receiving acupuncture reported significantly lower scores on the Brief Pain Inventory–Short Form (BPI).

“We have shown consistently, with multiple measures assessing pain and stiffness, that true acupuncture generated better outcomes than either control group in a large multicenter trial,” said lead author Dawn L. Hershman, MD, leader of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Medical Center. “Acupuncture provides a nonpharmacologic option that can improve symptoms and possibly increase AI adherence and subsequent breast cancer outcomes.”

AIs can reduce both early breast cancer recurrence and mortality. Dr. Hershman noted that these agents are effective in the adjuvant setting and for prevention “but we know that it doesn’t work if you don’t take it. Noncompliance is a major problem among women taking hormonal therapy.”

Noncompliance is multifactorial and one of the main reasons women discontinue their therapy early is because of arthralgias or joint discomfort. “We were interested in a nonpharmacologic intervention, to assess whether or not we could control these symptoms.”

Dr. Hershman pointed out acupuncture provides a safe and effective alternative for patients reluctant to take a prescription medication that can result in other side effects. “Identification of nonopioid options for pain control is a public health priority,” she said.

Acupuncture is a popular nonpharmacologic modality and widely used for a number of indications. Several single-institution studies have suggested that it may be useful for controlling AI-associated arthralgias, while other studies have not demonstrated a benefit.

In this trial, the authors evaluated the efficacy of acupuncture, compared with sham acupuncture or waitlist control, in the treatment of AI associated arthralgia in a large population of patients. The study was conducted at 11 centers.

The cohort comprised 226 postmenopausal women diagnosed with early-stage, hormone receptor–positive breast cancer who were receiving treatment with AIs. The primary endpoint was the decline in joint pain as measured by BPI-SF at 6 weeks, and to assess the duration of the effect, the women were followed for an additional 12 weeks.

Within this group, 110 were randomized to true acupuncture; 59 to sham acupuncture, and 57 to waitlist control (no treatment). Patients receiving true or sham acupuncture had sessions three times a week for 6 weeks followed by one session per week for 6 more weeks. Pain status was reported at baseline, during treatment, and then afterwards, using a variety of measurement tools including the BPI-SF, which is a self-administered 14-item questionnaire that evaluates pain severity on a 0-10 scale, and the impact of pain on activities of daily living.

At 6 weeks, the true acupuncture treatment arm reported significantly lower BPI worst pain scores than those in the sham acupuncture and the waitlist control arms. The mean BPI worst pain for the true acupuncture arm was 0.92 points lower than the sham acupuncture arm (P = .01) and 0.96 points lower than the waitlist control arm (P = .01). The proportion of patients experiencing a large reduction in BPI worst pain (greater than 2) was significantly greater in the true acupuncture arm, compared with the other groups: 58% versus 33% percent and 31%, respectively. The differences continued to remain statistically significant at 24 weeks, even though the treatment only continued for 12 weeks.

Associated adverse effects were minimal with true and sham acupuncture and limited to grade 1 bruising.

The cost of the 12-week intervention was about $1,250 or $65-$75 a session. “We feel that there is now sufficient evidence to support insurance coverage of acupuncture of AI arthralgia.”

In a discussion of the paper, Dr. Anne Partridge, from the Dana Farber Cancer Center, noted that it is imperative to seek new ways to improve outcomes in breast cancer, and AIs are contributing to that. However, she echoed the concern that nonadherence to treatment is a “tremendous problem” and hampers the clinical effectiveness of AI therapy.

The rate of discontinuation during the first year of therapy is 20% within the first year and up to 40% of patients do not take them daily. Both early discontinuation and nonadherence contribute to mortality.

Based on these results from the largest randomized controlled trial looking at acupuncture in this setting, should physicians be recommending acupuncture to patients prescribed AI therapy?

“The short answer is, why not?” said Dr. Partridge, “And that we should be recommending it for some of our patients.”

However, there are a number of issues that need to be addressed, she added. The duration of treatment is not known, and the need for follow-up treatment or the frequency of it is not known. The generalizability of it is also unclear when looking at a larger population, and acupuncture is highly operator dependent.

“There are cost and access issues, and insurance right now offers very limited coverage,” she said.

Importantly, Dr. Partridge emphasized, “We know that it will help symptoms, but will it improve adherence to AI?”

It may improve adherence for some patients, but “side effects are only one factor,” she said. “Adherence behavior is complicated. We need to figure out how to optimize these therapies in our patients.”

This study was supported by the National Institutes of Health National Center for Complementary and Integrative Health and the Office of Research on Women’s Health, and grants from the NIH/National Cancer Institute Division of Cancer Prevention. Dr. Hershman declared no conflicts of interest. Dr. Partridge had no disclosures.

empty-wheelchair-parked-in-hospital-pict
digitwin.png

Illumina, Chinese Children's Hospital to Launch Newborn Sequencing Study

Apr 23, 2019

 

| 

staff reporter

 

NEW YORK (GenomeWeb) – Illumina and the Children's Hospital of Fudan University in China plan to launch a study of whole-genome sequencing in the hospital's neonatal intensive care unit to determine whether it can be used as a diagnostic for critically ill infants, Illumina said this week.

According to Illumina, the researchers plan to enroll 200 patients and compare the diagnostic rate of rapid WGS with genetic diagnostic methods such as microarray analysis and gene panel sequencing.

The researchers will also compare the time it takes to reach a diagnosis, impact on the patient's prognosis, and turnaround time.

Illumina will provide the sequencing reagents and the Children's Hospital of Fudan University will conduct the testing and data analysis and also be responsible for reporting results and providing genetic consultations with family members.

The hospital is also a sponsor of the Newborn Genome Project, which is creating a genome database for newborns in China in order to develop better methods for detecting genetic diseases in newborns and to establish standards for neonatal genetic diseases.

UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment

Dec 13, 2019

 

| 

staff reporter

 

NEW YORK – Researchers from the Institute of Cancer Research, London and the Royal Marsden NHS Foundation Trust have presented data demonstrating that blood-based genotyping assays can accurately detect specific biomarkers and potentially be used to guide targeted treatment of metastatic breast cancer. 

The researchers used Guardant Health's liquid biopsy assay and Bio-Rad Technologies' droplet digital PCR (ddPCR) testing to identify errors — including mutations in the HER2, ESR1 and AKT1 genes — in circulating tumor DNA (ctDNA) that had been shed into the patients' bloodstream. 

During a presentation this week at the San Antonio Breast Cancer Symposium (SABCS), Nicholas Turner, molecular oncology professor at the Institute of Cancer Research, explained that his team wanted to solve the issue of genotyping breast cancer tumors without having to perform multiple biopsies. Turner highlighted the need for prospective studies to assess the accuracy of ctDNA testing in routine practice and the potential of these tools to guide targeted therapy without requiring solid tissue testing. 

With funding from Stand Up To Cancer (a fundraising campaign from Cancer Research UK and Channel 4) Turner's team therefore launched an ongoing prospective study, called "plasmaMATCH," to examine the clinical utility of ctDNA for metastatic breast cancer detection. The group enrolled a total of 1,044 patients with advanced breast cancer who had either progressed on prior drug therapy or relapsed within a year after adjuvant chemotherapy. 

The researchers analyzed ctDNA in blood samples from patients using the Guardant360 sequencing-based assay and Bio-Rad's ddPCR as an orthogonal method. Patients with identified mutations could also enroll in a treatment arm of the study that matched their mutation. 

Turner and his team split the patient population into three major cohorts depending on specific genetic errors found in ctDNA: ESR1 mutations, HER2 mutations, and AKT-1 mutations in estrogen-receptor-positive breast cancer. The researchers also added a fourth cohort that had AKT-1 and PTEN mutations based on both ctDNA and tumor sequencing results, as well as a fifth group with triple-negative breast cancer without mutations. 

While Turner's team's initially aimed to measure the response rate of targeted therapies matched to mutations in ctDNA without tissue testing, the researchers also monitored the frequency of mutations, accuracy of testing, proportion of patients entering a treatment cohort, and the activity in clonality-dominant versus subclonal mutations. Turner's team discovered that 784 patients who had cfDNA testing done with both Guardant360 and ddPCR had "very strong agreement" of between 96 and 99 percent. Comparing the ctDNA to the patients' tumor samples to validate the plasmaMATCH findings, the researchers found that the liquid biopsy assay had an overall sensitivity of 93 percent. 

Guardant360 also identified several more targetable alterations than hotspot testing, including over 35 percent more PIK3CA mutations that can be targeted by US Food and Drug Administration-approved therapies. The assay also detected significantly more ESR1 mutations and found previously undetected microsatellite instability and ERBB2 mutations.   

The researchers provided 142 patients that had specific identified mutations experimental targeted therapies as part of the study, and they plan to test the treatments that showed initial promise in larger clinical trials. 

The researchers now believe that they can use blood testing to identify rare subtypes of breast cancer, in addition to potentially replacing more invasive methods of breast cancer detection. 

"We have now confirmed that blood tests can quickly give us a bigger picture of the mutations [that] are present within multiple tumors throughout the study," Turner said in a statement.  

"We show that circulating tumor DNA testing offers a simple, efficient, and fast method of tumor genotyping," Turner also noted during the presentation at SABCS. "The patients with mutations identified in their ctDNA have efficacy with matching target[ed] therapies." 

The researchers believe the blood-based assays are now reliable enough to be applied routinely by clinicians after receiving regulatory approval.

"As the number of treatment-relevant genomic alterations in metastatic breast cancer continues to grow, it is critical that oncologists have a simple and reliable way to comprehensively test for this information about their patients," Guardant Health Global Chief Medical Officer Rick Lanman said in a statement. "Guardant360 detected changes in the genome picture over time … and also identifies targetable but uncommon genomic biomarkers."

1c8b9b577cc41266ebab5e65ff8f3de8.jpg
090320_COVID_Test_0111-1024x682.jpg
05b50bc878af8f403a01848035fa3a86.jpg
7d54e3018152c4d0b389e55596039404.jpg
4deac0802d4054a8a85b3f3d256911aa.jpg
hocit999 - コピー_ページ_16.jpg
hocit999_ページ_6.jpg
bottom of page